CTLA4-lg (Abatacept) for the Prevention of Abnormal Glucose Tolerance and Diabetes in Relatives At-Risk for Type 1 Diabetes
The goal of this study is to learn if the drug Abatacept will help delay or prevent the onset of abnormal glucose levels and/ or the onset of type 1 diabetes by delaying or preventing beta cell destruction. For more informatin about this study, contact Roberta Cook by phone at 352-294-5759 or email firstname.lastname@example.org
Keywordstype 1 diabetes, trialnet, prevention
Principal InvestigatorDesmond Schatz, M.D.
Begin a new search for other research studies
Studies listed on this site have been approved by a UF Institutional Review Board (IRB), which works to ensure the welfare and rights of research participants as required by federal regulations. Study listings are provided by the UF Clinical and Translational Science Institute in collaboration with UF research teams and the UF IRBs.